ICD-10-CM Diagnosis Code (2025)
Official Description for Z79.81
Long term (current) use of agents affecting estrogen receptors and estrogen levels
Coding Notes & Guidelines for Z79.81
hormone replacement therapy (Z79.890)
- , if applicable:
- malignant neoplasm of breast (C50.-)
- malignant neoplasm of prostate (C61)
- code, if applicable, to identify:
- estrogen receptor positive status (Z17.0)
- family history of breast cancer (Z80.3)
- genetic susceptibility to malignant neoplasm (cancer) (Z15.0-)
- personal history of breast cancer (Z85.3)
- personal history of prostate cancer (Z85.46)
- postmenopausal status (Z78.0)
- Long term (current) use of raloxifene (Evista)
- Long term (current) use of tamoxifen (Nolvadex)
- Long term (current) use of toremifene (Fareston)
- Long term (current) use of anastrozole (Arimidex)
- Long term (current) use of exemestane (Aromasin)
- Long term (current) use of letrozole (Femara)
- Long term (current) use of estrogen receptor downregulators
- Long term (current) use of fulvestrant (Faslodex)
- Long term (current) use of gonadotropin-releasing hormone (GnRH) agonist
- Long term (current) use of goserelin acetate (Zoladex)
- Long term (current) use of leuprolide acetate (leuprorelin) (Lupron)
- Long term (current) use of megestrol acetate (Megace)
Parent Code (Less Specific):
About ICD-10-CM Code Z79.81 (Long term)
ICD-10-CM code Z79.81 is a billable or specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2025 edition of ICD-10-CM Z79.81 became effective on October 1, 2024.
This page provides detailed information about Z79.81 - Long term (current) use of agents affecting estrogen receptors and estrogen levels. It includes common terminology, coding guidelines such as "Includes," "Excludes1," and "Excludes2" notes, and information on required 7th characters. Utilizing this information correctly is essential for accurate medical coding and claims submission for conditions like Long term.